This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
Yang J, et al. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Applied Health Economics and Health Policy : 28 Jan 2021. Available from: URL: http://doi.org/10.1007/s40258-021-00637-5
Rights and permissions
About this article
Cite this article
Bevacizumab biosimilar cost saving in patients with cancer. PharmacoEcon Outcomes News 871, 3 (2021). https://doi.org/10.1007/s40274-021-7441-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7441-5